[Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
Saitta
A
A
Bonaiuto
M
M
Lanzafame
F
F
Mileto
A
A
Pernice
F
F
Cinquegrani
M
M
Mazza
G
G
Micali
G
G
Pangallo
A
A
Fodale
P
P
D000328:Adult; D000368:Aged; D001054:Apolipoproteins A / Q000097:blood*; D001055:Apolipoproteins B / Q000097:blood*; D001629:Bezafibrate / Q000008:administration & dosage / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
D001054:Apolipoproteins A; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008055:Lipids; D014280:Triglycerides; D002784:Cholesterol; D001629:Bezafibrate
Valutazione delle apoproteine A e B, delle lipoproteine e dei lipidi plasmatici durante trattamento con bezafibrato in varie forme di iperlipoproteinemia.